Posted: 2:15 pm Wed, April 17, 2013
By Daily Record Staff
Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, said it received approval from the Food and Drug Administration to begin a Phase II trial using spinal cord-derived human neural stem cells to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Already a paid subscriber but not registered for online access yet? For instructions on how to get premium web access, click here.